l style=”list-style-type: disc;” class=” list-paddingleft-2″>
The “New Crown Vaccine R&D Race” is becoming increasingly fierce, and “The Lancet” pushes the positive clinical data of “CanSino Bio and Chen Wei Team”
In the context of fighting the new crown, the research and development of the new crown vaccine is advancing vigorously.
The teams with faster R&D progress come from China, the United States and the United Kingdom, and all vaccine projects have entered clinical trials, and the competition is becoming increasingly fierce.
The domestic CanSino Bio and Chen Wei team are developing a recombinant Ad5 adenovirus vector vaccine. The team has international-level technology and leading research and development progress, so it has become the focus of close attention from the market.
Recently, there has been a breakthrough in the research and development of this vaccine-the international medical papers journal “The Lancet” announced the world’s first phase II clinical trial data of the recombinant new coronavirus vaccine (Ad5-nCoV). The results show that the vaccine is safe and can cause a significant immune response in one shot, which supports the vaccine’s entry into the Phase III effectiveness study. The vaccine was jointly developed by Cansino Biology and the Institute of Biological Engineering of the Academy of Military Sciences. On June 25, the vaccine has been approved for the military’s special needs…(For more information please click here)
Consumption
Financing disclosure:
-
To create mixed nut snacks, “Boundless” received £1 million financing
According to foreign mediafoodbevrecently, the British brand “Boundless< span style="letter-spacing: 0px;">” received £1 million in financing to promote the development of its brand. This round of financing comes from existing angel investors and high-net-worth individuals.
In 2017, “Boundless” in the United Kingdom was launched by Ca